# Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders

> **NCT02266524** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 48 (actual)

## Conditions studied

- Urination Disorders

## Interventions

- **DRUG:** Tamsulosin hydrochloride, very low dose
- **DRUG:** Tamsulosin hydrochloride, low dose
- **DRUG:** Tamsulosin hydrochloride, medium dose
- **DRUG:** Tamsulosin hydrochloride, high dose

## Key facts

- **NCT ID:** NCT02266524
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2005-04
- **Final completion:** —
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2014-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02266524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02266524, "Pharmacokinetics, Safety and Tolerability of Tamsulosin Hydrochloride in Children With Voiding Disorders". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02266524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*